From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

From the Department of Biostatistics, Bloomberg School of Public Health (J.M., E.M.S., A.E., C.M.C.) and Department of Neurology, Division of Brain Injury Outcomes (N.L.U., D.F.H.), Johns Hopkins Medical Institutions, Baltimore, MD; and Department of Neurosurgery, David Geffen School of Medicine at UCLA (N.M., P.V.).

Abstract

Background and Purpose—The location of intracerebral hemorrhage (ICH) is currently described in a qualitative way; we provide a quantitative framework for estimating ICH engagement and its relevance to stroke outcomes.

Methods—We analyzed 111 patients with ICH from the Minimally Invasive Surgery Plus Recombinant-Tissue Plasminogen Activator for Intracerebral Evacuation (MISTIE) II clinical trial. We estimated ICH engagement at a population level using image registration of computed tomographic scans to a template and a previously labeled atlas. Predictive regions of National Institutes of Health Stroke Scale and Glasgow Coma Scale stroke severity scores, collected at enrollment, were estimated.

Results—The percent coverage of the ICH by these regions strongly outperformed the reader-labeled locations. The adjusted R2 almost doubled from 0.129 (reader-labeled model) to 0.254 (quantitative location model) for National Institutes of Health Stroke Scale and more than tripled from 0.069 (reader-labeled model) to 0.214 (quantitative location model). A permutation test confirmed that the new predictive regions are more predictive than chance: P<0.001 for National Institutes of Health Stroke Scale and P<0.01 for Glasgow Coma Scale.